Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ekatherine Asatiani"'
Autor:
Francis Seguy, Jean-Jacques Kiladjian, Feng Zhou, Haris Ali, Ekatherine Asatiani, Jason Gotlib, Sanjay R. Mohan, Srdan Verstovsek, Francesca Palandri, Stephen T. Oh
Publikováno v:
Cancer Research. 81:CT216-CT216
Background: Anemia represents a therapeutic challenge in patients with myelofibrosis (MF). ALK2 activation is associated with elevated hepcidin, which may contribute to anemia of chronic disease and anemia due to hematologic malignancies, and is asso
Autor:
Stephen T. Oh, Francis Seguy, Sanjay R. Mohan, Srdan Verstovsek, Haris Ali, Feng Zhou, Ekatherine Asatiani, Jason Gotlib
Publikováno v:
Blood. 136:3-3
Background: Anemia represents a challenge in the management of patients with myelofibrosis (MF); at least a third of patients with MF are reported to have hemoglobin levels Methods: INCB 00928-104 (NCT04455841) is a phase 1/2, open-label, multicenter
Autor:
Hiroshi Kitamura, Natalia Oliveira, Jason Howe, Matthew D. Galsky, Thomas Powles, Robert Dreicer, Andrea Necchi, Hui-Ling Zhen, Ekatherine Asatiani
Publikováno v:
Journal of Clinical Oncology. 38:TPS592-TPS592
TPS592 Background: Fibroblast growth factor receptor (FGFR) 3 gene alterations (GAs) are involved in UC pathogenesis. Pts with metastatic UC and FGFR3 GAs express low programmed cell death ligand 1 (PD-L1) levels; combination with FGFR inhibitors may
Autor:
Ekatherine Asatiani, Ping Jiang, Eric Van Cutsem, Arndt Vogel, Hui-Ling Zhen, Tanios Bekaii-Saab, Lorenza Rimassa, Luis Féliz, Juan W. Valle, Mitesh J. Borad, Christine F. Lihou, Teresa Macarulla, Junji Furuse, John Bridgewater, Harpreet Wasan, Tatsuya Ioka, Davide Melisi
Publikováno v:
Journal of Clinical Oncology. 38:TPS592-TPS592
TPS592 Background: For advanced CCA, standard of care 1L systemic treatment is GEM + CIS. Genetic alterations in intrahepatic CCA provide potential therapeutic targets. Fibroblast growth factor receptor (FGFR) 2 gene rearrangements driving CCA tumori
Publikováno v:
Journal of Clinical Oncology. 38:588-588
588 Background: Most cholangiocarcinoma (CCA) patients (pts) are diagnosed with advanced disease and are ineligible for surgery. FGFR2 fusions or rearrangements are present in 10–16% of pts with intrahepatic CCA (iCCA) and are reported to be oncoge
Autor:
Christine E. Swenson, Lawrence D. Mayer, Alan F. List, Steven L. Allen, Jeffrey E. Lancet, Arthur C. Louie, Eric J. Feldman, Ekatherine Asatiani, Ellen K. Ritchie, Jonathan E. Kolitz, Gail J. Roboz
Publikováno v:
Journal of Clinical Oncology. 29:979-985
Purpose This phase I dose-escalation trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities, and pharmacokinetics of CPX-351. Patients and Methods CPX-351 induction was administered on days 1, 3, and 5 by 90-minute infu
Deletion, Methylation, and Expression of the NKX3.1 Suppressor Gene in Primary Human Prostate Cancer
Autor:
Bassem R. Haddad, Elizabeth Rodriguez Ortner, Edward P. Gelmann, Antai Wang, Wen Xin Huang, Luciane R. Cavalli, Ekatherine Asatiani
Publikováno v:
Cancer Research. 65:1164-1173
NKX3.1 is a prostate-specific homeoprotein and tumor suppressor that is affected by the loss of 8p21 in prostate cancer. In mice, Nkx3.1 haploinsufficiency results in prostatic dysplasia and complements cancer formation induced by loss of other suppr
Autor:
Craig M. Kessler, Bruce D. Cheson, Metin Ozdemirli, Ekatherine Asatiani, Philip Cohen, Blanche Mavromatis
Publikováno v:
American Journal of Hematology. 77:144-146
Monoclonal gammopathy is a well-recognized occurrence in splenic marginal zone lymphoma (MZL); however, its prevalence has never been reported in extranodal MZL (ENMZL). We present results of a retrospective analysis of 26 patients with newly diagnos
Autor:
Elliott F. Winton, Ekatherine Asatiani, Hagop M. Kantarjian, William V. Walsh, Sameer A. Parikh, Aaron D. Schimmer, Srdan Verstovsek, Khaled El-Shami
Publikováno v:
Clinical lymphoma, myelomaleukemia. 10(4)
Background Myelofibrosis (MF) is a disease characterized by the overexpression of the antiapoptotic BCL-2 family of proteins (eg, BCL-X L and MCL-1). Patients and Methods We conducted a multicenter, open-label, noncomparative phase II study of obatoc
Publikováno v:
Leukemialymphoma. 49(1)
Seeding of malignant cells along a biopsy tract is an uncommon complication of percutaneous biopsy. This occurrence is relatively more common in hepatocellular or renal cell carcinomas than in pati...